Bifogade filer
Realheart Receives Patent Approval in Europe
Kurs
-0,72%
Likviditet
0,36 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-05-29 | N/A | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2026-05-28 | N/A | Årsstämma |
| 2026-02-19 | - | Bokslutskommuniké 2025 |
| 2025-12-16 | - | Extra Bolagsstämma 2025 |
| 2025-08-28 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-12 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2025-06-11 | - | Årsstämma |
| 2025-05-15 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-26 | - | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Split HEART 100:1 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-11-05 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-10 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2024-06-07 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-24 | - | Extra Bolagsstämma 2023 |
| 2023-11-16 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-16 | - | Årsstämma |
| 2023-06-15 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2023-06-14 | - | Årsstämma |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-15 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2022-06-14 | - | Årsstämma |
| 2022-05-20 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-08-05 | - | Extra Bolagsstämma 2021 |
| 2021-05-20 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-03 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-08-04 | - | Extra Bolagsstämma 2020 |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-05-19 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2020-05-18 | - | Årsstämma |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-27 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2019-03-26 | - | Årsstämma |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | Årsstämma |
| 2018-05-17 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-11 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-27 | - | Extra Bolagsstämma 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-31 | - | Kvartalsrapport 2017-Q1 |
| 2017-05-11 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2017-05-10 | - | Årsstämma |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
| 2016-11-24 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-11 | - | Kvartalsrapport 2016-Q1 |
| 2016-05-10 | - | Årsstämma |
| 2016-04-20 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-11-12 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-26 | - | Kvartalsrapport 2015-Q1 |
| 2015-05-21 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2015-05-20 | - | Årsstämma |
| 2015-02-18 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Västerås, Sweden, February 11, 2026 – Scandinavian Real Heart AB (publ) announces today that the company has been granted patent approval by the European Patent Office (EPO). The patent concerns both the core technology of Realheart® TAH, pertaining to the structure and function of the total artificial heart, and the integrated feedback mechanism that regulates the device’s cardiac output. The recent approval grants a unitary patent protecting the technology in 17 EU countries, including Realheart’s key markets, France and Germany, and its home market, Sweden, through 2041.
Realheart is developing Realheart® TAH, the first total artificial heart that mimics the structure and function of the native human heart. The recently approved patent covers a core technology of Realheart® TAH, producing accurate and safe pressure measurements. By enabling real-time monitoring, the patented sensor enables automated control of artificial hearts and circulatory support systems, such as Realheart® TAH. The feature is designed to provide a meaningful treatment alternative for patients awaiting a heart transplant while providing benefits that may increase the quality of life. The structural design of Realheart® TAH aims to decrease risk factors commonly associated with currently approved artificial heart treatment devices, e.g., stroke, internal bleeding, and anaemia.
Region: European Patent Office (EPO)
Patent number: 4120893
Expiration date: March 18, 2041
For more information, please contact:
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se
About Us
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se
Attachments
Realheart Receives Patent Approval in Europe